Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
| Autor: | Zhu, Feng-Cai ***, Guan, Xu-Hua, Li, Yu-Hua, Huang, Jian-Ying, Jiang, Tao, Hou, Li-Hua, Li, Jing-Xin, Yang, Bei-Fang, Wang, Ling, Wang, Wen-Juan, Wu, Shi-Po, Wang, Zhao, Wu, Xiao-Hong, Xu, Jun-Jie, Zhang, Zhe, Jia, Si-Yue, Wang, Bu-Sen, Hu, Yi, Liu, Jing-Jing, Zhang, Jun, Qian, Xiao-Ai, Li, Qiong, Pan, Hong-Xing, Jiang, Hu-Dachuan, Deng, Peng, Gou, Jin-Bo, Wang, Xue-Wen, Wang, Xing-Huan **, Chen, Wei * |
|---|---|
| Zdroj: | In The Lancet 15-21 August 2020 396(10249):479-488 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|